Survival Predictors After Donor Transplantation for Hematologic Malignancy Identified

Share this content:
Biggest predictors of survival following hematopoietic transplantation are donor age and donor-recipient human leukocyte antigen-match.
Biggest predictors of survival following hematopoietic transplantation are donor age and donor-recipient human leukocyte antigen-match.

The biggest predictors of survival following hematopoietic transplantation (HCT) for patients with hematologic malignancy are donor age and donor-recipient human leukocyte antigen (HLA)-match, according to an article published online ahead of print in Blood.1

Investigators evaluated the association between donor characteristics (ie, age, sex, parity, cytomegalovirus serostatus, HLA-match, and blood group ABO match) and survival following transplantation.

Logistic or Cox regression models were used to examine the associations of donor characteristics with transplantation outcomes in 2 independent datasets: 1988 through 2006 (N=6,349; training cohort), and 2007 through 2011 (N=4,690; validation cohort).

Results after adjusting for patient disease and transplantation characteristics showed a survival benefit with grafts from young donors (18 to 32 years) who were HLA-matched to recipients (P < .001).

RELATED: Hematopoietic Cell Transplant Linked With Better Survival Outcomes

There was a 5.5% increase in the haqard ratio for overall mortality with every 10-year increment in age. Differences in HLA were associated with a decrease in survival.

Sex, parity, and cytomegalovirus serostatus were not linked to survival.

Investigators concluded that the effect of ABO matching on survival is modest and merits further study.

Reference

  1. Kollman C, Spellman SR, Zhang M-J, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy [published online ahead of print November 2, 2015]. Blood. doi: 10.1182/blood-2015-08-663823.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters